Denali Cap Acqsn Stock Price, News & Analysis

Denali Capital Acquisition Corp. (historically associated with the Nasdaq trading symbol DECAU for its units) is described in its public disclosures as a blank check company incorporated as a Cayman Islands exempted company. According to the company’s press releases, it was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

The company’s units, each consisting of one Class A ordinary share and one redeemable warrant, were approved for listing on The Nasdaq Global Market under the symbol DECAU in connection with its initial public offering. A press release states that, after the securities comprising the units began separate trading, the Class A ordinary shares and warrants were expected to trade under the symbols DECA and DECAW, respectively, on Nasdaq.

Subsequent SEC filings show that Denali Capital Acquisition Corp. is an emerging growth company incorporated in the Cayman Islands. Its filings identify it as an issuer of units, Class A ordinary shares with a par value of $0.0001 per share, and warrants, with each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share. Later Form 8-K filings indicate that these securities became quoted on over-the-counter markets under the symbols DNQUF for units and DNQAF and DNQWF for the Class A ordinary shares and warrants, respectively.

A Form 25 filed with the SEC by Nasdaq Stock Market LLC provides notice of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 for the Class A ordinary shares, units, and warrants of Denali Capital Acquisition Corp. This filing confirms that the securities were removed from listing on Nasdaq, although the company continues to report under the Exchange Act and its securities are quoted on OTC markets as reflected in later 8-K filings.

Company press releases explain that Denali Capital Acquisition Corp. seeks to consummate an initial business combination and that its governing documents allow for extensions of the deadline to complete such a transaction. One press release notes that shareholders approved amendments to the company’s amended and restated memorandum and articles of association to extend the date by which it must consummate an initial business combination, with the company depositing funds into its trust account to extend this period on a monthly basis.

More recent Form 8-K filings describe a planned business combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of Scilex Holding Company. Under an agreement and plan of merger, Denali Merger Sub Inc., a wholly owned subsidiary of Denali Capital Acquisition Corp., is expected to merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali Capital Acquisition Corp. The filings refer to this transaction as the Business Combination and note that amendments to the merger agreement were executed to modify definitions related to the exchange ratio and merger consideration while maintaining a 1.25-to-1 exchange ratio.

In its SEC communications, Denali Capital Acquisition Corp. emphasizes that detailed information about the proposed Business Combination, including the terms of the merger and interests of directors and executive officers, is contained in a Registration Statement on Form S-4 filed with the SEC, which includes a proxy statement/prospectus for its shareholders. The company indicates that shareholders will receive definitive proxy materials and are encouraged to review these documents for a full description of the proposed transaction.

Denali Capital Acquisition Corp. has also filed a Form 12b-25 (Notification of Late Filing) indicating that it was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for a specified period by the prescribed due date due to delays in completing its financial statements and related disclosures. In that filing, the company states that it anticipated filing the quarterly report within the extension period permitted by SEC rules and that it did not expect a significant change in results of operations from the corresponding period of the prior year.

Overall, Denali Capital Acquisition Corp. functions as a special purpose acquisition company (SPAC) whose primary objective, as stated in its press releases and SEC filings, is to identify and complete a business combination with one or more target businesses. Its public disclosures focus on its capital structure (units, Class A ordinary shares, and warrants), its status as a Cayman Islands exempted company, its efforts to extend the time available to complete a business combination, and its entry into a merger agreement involving Semnur Pharmaceuticals, Inc.